BFA
VKTX icon

BlackRock Fund Advisors’s Viking Therapeutics VKTX Stock Holding History

BlackRock Fund Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1K Hold
703
– – ﹤0.01% 4201
2016
Q3 		$1K Buy
703
+57
+9% +$75 ﹤0.01% 4229
2016
Q2 		$1K Buy
646
+64
+11% +$84 ﹤0.01% 4289
2016
Q1 		$1K Buy
+582
New +$1.17K ﹤0.01% 4292

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

BlackRock Fund Advisors's VKTX Position: Q4 2016 in Review

BlackRock Fund Advisors held its Viking Therapeutics (VKTX) position steady in Q4 2016 at 703 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #4201.

BlackRock Fund Advisors first reported a position in VKTX in Q1 2016 and has held it in 4 quarters since. 12 funds tracked by Wall St. Rank hold VKTX as of Q4 2016.

  • BlackRock Fund Advisors held 703 shares of Viking Therapeutics worth $1K as of Q4 2016.
  • BlackRock Fund Advisors left its Viking Therapeutics share count unchanged in Q4 2016.
  • Viking Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #4201 holding.
  • BlackRock Fund Advisors first reported a position in Viking Therapeutics in Q1 2016 and has held it in 4 quarters since.
  • 12 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.